FEATURE
risk for VTE in whom the use of compression stockings
or LMWH may not be feasible, the use of aspirin can be
considered, rather than no VTE prophylaxis. 3
What to Tell Patients
Despite – or perhaps because of – inconsistent data about
the prevalence of travel-related VTE, clinicians routinely
field patient questions about what measures they should
take to prevent VTE before a long trip.
“In the typical scenario, a patient is referred to me and
says, ‘I’m going to take a flight to Australia in a month. Is
there anything I can do to reduce risk?’” Dr. Kahn said.
There are several simple non-pharmacologic
recommendations providers can offer to provide patients
with peace of mind, Marc Carrier, MD, MSc, FRCPC,
professor of medicine in the department of medicine at the
University of Ottawa, told ASH Clinical News. First, and
easiest, is a group of commonsense recommendations, for
which there are not much supportive data, but which are
unlikely to be harmful.
These include the recommendations Dr. Kahn outlined,
like walking around the cabin and staying hydrated, as well
as avoiding alcohol consumption. The Centers for Disease
Control and Prevention also recommends passengers
perform leg exercises during long flights to increase cirula-
tion. 11
Dr. Crowther added that patients with strong risk
factors for VTE should be counseled to avoid air travel.
“If you just had surgery on your knees, for example, or
are undergoing hormonal therapy as part of fertility
treatments, don’t travel unless you really need to,” he said.
“Avoid piling on risk factors.”
Finally, if patients are at high risk for VTE and can
NOW APPROVED
Effi cacy in treatment-naïve patients (N=29) 1
72%
CR/CRc
rate*
90%
ORR
45%
bridged to stem cell
transplantation
* CRc = clinical complete response; defi ned as complete response with residual skin abnormality not indicative of active disease. 2
CR = complete response; ORR = overall response rate.
Median duration of CR/CRc has not yet been reached in treatment-naïve
patients (range, 1.3-32.2+ months). 1
Median overall survival has not yet been reached; median follow-up 23.0 months
(range, 0.2-41.0+ months). 1
In the pivotal cohort, treatment-naïve patients (N=13) achieved a 54% CR/CRc rate,
77% ORR, and 46% bridged to stem cell transplantation. 1,2
ELZONRIS TM (tagraxofusp-erzs) was evaluated in treatment-naïve and previously-treated patients with BPDCN in
an open-label, multicenter clinical study (N=44). The pivotal cohort consisted of 13 treatment-naïve patients. 1,2
VISIT ELZONRIS.COM/HCP FOR MORE INFORMATION.
Hypersensitivity Reactions ADVERSE REACTIONS:
• ELZONRIS can cause severe hypersensitivity reactions. Grade 3
or higher events were reported in 10% of patients in clinical
trials. Monitor patients for hypersensitivity reactions during
treatment with ELZONRIS. Interrupt ELZONRIS infusion and
provide supportive care as needed if a hypersensitivity
reaction should occur. If the reaction is severe, discontinue
ELZONRIS permanently
Hepatotoxicity
• Elevations in liver enzymes can occur with ELZONRIS.
Grade 3 or higher elevations in liver enzymes occurred
in approximately 40% of patients in clinical trials
• Monitor alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) prior to each infusion with ELZONRIS.
Temporarily withhold ELZONRIS if the transaminases rise to
greater than 5 times the upper limit of normal (ULN) and
resume treatment upon normalization or when resolved The most common adverse reactions in the clinical trials
(incidence ≥ 30%) are capillary leak syndrome, nausea, fatigue,
peripheral edema, pyrexia, and weight increase. The most
common laboratory abnormalities (incidence ≥ 50%) are
decreases in albumin, platelets, hemoglobin, calcium,
sodium, and increases in glucose, ALT, and AST.
Please see Brief Summary of full Prescribing Information,
including Boxed WARNING, on the following pages.
To report SUSPECTED ADVERSE REACTIONS, contact Stemline
Therapeutics, Inc. at 1- 877-332-7961 or contact the FDA at
1- 800-FDA-1088 or www.fda.gov/medwatch.
References: 1. Data on fi le. Stemline Therapeutics, Inc. 2. ELZONRIS [prescribing
information]. New York, NY, US: Stemline Therapeutics, Inc.; December 2018.